CLRB Cellectar Biosciences Inc.

2.44
-0.02  -1%
Previous Close 2.46
Open 2.44
Price To Book 1.54
Market Cap 22,926,328
Shares 9,396,036
Volume 14,014
Short Ratio
Av. Daily Volume 101,139

NewsSee all news

  1. Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FLORHAM PARK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  2. Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

    Data presented at the 17th International Myeloma Workshop Patients in Cohort 6 achieved a meaningful clinical benefit with a 50% overall response rate and 100% disease control FLORHAM PARK, N.J., Sept. 16, 2019

  3. Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

    FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  4. Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

    FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2019.
CLR 131
Various lymphoma
Phase 1 data September 14, 2019 noted 50% ORR.
CLR 131
Multiple myeloma
Phase 1 trial to continue to higher dose - August 14, 2019.
CLR 131 (CLOVER-2)
Solid tumors

Latest News

  1. Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    FLORHAM PARK, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  2. Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma

    Data presented at the 17th International Myeloma Workshop Patients in Cohort 6 achieved a meaningful clinical benefit with a 50% overall response rate and 100% disease control FLORHAM PARK, N.J., Sept. 16, 2019

  3. Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019

    FLORHAM PARK, N.J., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the

  4. Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop

    FLORHAM PARK, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the